Real-world evaluation of the transition between originator and follow-on glatiramer acetate in people with multiple sclerosis: the “GA transition” study
Switching from originator GA to CO did not influence clinical outcomes or safety. These findings support the therapeutic equivalence of the two formulations in real-world clinical practice, by supporting previous evidence from randomized trials.
Authors
- Cinzia Cordioli
- P. Cavalla
- Alessio Carbone (ORCID: https://orcid.org/0009-0008-9907-3299)
- Beatrice Giovannini (ORCID: https://orcid.org/0009-0008-7358-1797)
- Alice Laroni
- Giacomo Lus
- Mattia Pozzato
- Sarah Rasia
- Pietro Annovazzi
- Elisabetta Signoriello
- Maria Pia Sormani
- Sara La Gioia
- Alessia Di Sapio
- Chiara Zecca
- Irene Schiavetti
- Valentina Torri Clerici
Institutions
- University of Pisa (IT)
- Associazione Italiana Sclerosi Multipla (IT)
- Laboratory for Biomedical Neurosciences (CH)
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- Ospedale Papa Giovanni XXIII (IT)
- Krankenhaus Meran (IT)
- University of Campania "Luigi Vanvitelli" (IT)
- Ospedale San Luigi Gonzaga (IT)
- Fondazione IRCCS Istituto Neurologico Carlo Besta (IT)
- University of Turin (IT)
- Università della Svizzera italiana (CH)
- University of Genoa (IT)
Publication Details
- Journal
- Multiple Sclerosis and Related Disorders
- Published
- 2026-02-21
- DOI
- https://doi.org/10.1016/j.msard.2026.107088
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00